Shaping The Future Of Biologics Manufacturing

Avid Bioservices is beginning a new chapter under the leadership of its new Chief Executive Officer, Kenneth Bilenberg. Drawing on his extensive experience in the biopharma and CDMO industries, Bilenberg provides insight into the values and strategies that will define Avid's path forward.

He shares that the most important capability a CDMO offers is trust. This principle of reliability and delivering on promises is what drew him to Avid and is the company's greatest strength. Bilenberg emphasizes that a strong client relationship goes beyond transactions to become a true, collaborative partnership.

He sees major opportunities in the rapid growth of biologics and the reshoring of manufacturing to the US. Avid is well-positioned to meet this demand, offering the people, performance record, and capacity to support clients from small biotech to large pharma. Discover how this patient-centric vision will shape the future of biotherapeutics manufacturing.